Cancer can often come out of nowhere, especially leukemia, a type of blood cancer that doesn't typically run in families. Leukemia is a broad term for cancers that affect your blood cells. While we ...

Herein, we designed a photoactivatable OSI-027 prodrug, which allowed the release of OSI-027 after light irradiation to inhibit the mTOR signaling pathway, triggering autophagy and leading to cell ...

The distinctive pattern of cardioprotective and renoprotective effects of SGLT2 inhibitors is abolished by specific inhibition or knockdown of autophagy, AMPK, and sirtuins. In the clinical setting, ...

Retail investors can apply for a minimum of 1,000 shares, amounting to a minimum investment of Rs 1,35,000. The GMP for the company is around Rs 6 in the unlisted market ahead of the issue opening.

1Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany. 2Department of Pediatric Hematology and Oncology, University Medical Center Hamburg, Hamburg, Germany.

The GMP dropped to Rs 1 last week, before marginally improving to Rs 7 on 5 May, per investorgain.com. This cautious trend reflects muted sentiment for early gains, a departure from the euphoria seen ...

Reuters As of the latest update on May 6, 2025, at 01:56 PM, the GMP (Grey Market Premium) for Srigee DLM SME IPO stands at Rs 30, GMP monitoring site investorgain.com says. With a price band ...

According to Investorgain, the latest grey market premium (GMP) for the IPO stood at Rs 30 as of 6.00 PM on May 6. This indicates that the listing price will be Rs 129 apiece, with a potential gain of ...

Leukemia and lymphoma are cancers that affect white blood cells, but they are separate conditions. In some people, they can occur simultaneously. However, people with Hodgkin’s lymphoma are more ...

Ahead of listing, the company's shares were quoted trading at around ₹328 per share, reflecting a grey market premium (GMP) of ₹7 or 2.18 per cent over the issue price of ₹321, revealed the sources ...